Trial
NCT01077531
Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Arthritis, Rheumatoid
Intervention
Otelixizumab
Why stopped
The risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-08